Get these analyses to your inbox — https://axial.substack.com/
As always, if you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company — info@axialsprawl.com
Innovative Targeting Solutions (ITS) is a protein engineering company. On the other side of Vancouver from AbCellera, ITS is centered around a breakthrough technology to generate antibody diversity. Over 10 years in the making, ITS was founded by Michael Gallo, who previously led research on antibody generation at Amgen and Abgenix. With a business model similar to Adimab and AbCellera pursuing the same markets, what makes ITS an interesting case study is the uniqueness of their technology — HuTARG — and how the business used this as the basis to parter with some of the world’s largest drug developers. Given the value in ITS’ technology, the company serves as a useful starting point to identify new technical opportunities in antibody discovery and protein design in general.
Source: ITS
Key findings
- Antibodies have a set of problems where a company can build up a technical moat around: target solubility, potency maturation, tolerance, immunogenicity, rare specificities, diversity (i.e. CDRs).
